Biota partner to market
Monday, 30 March, 2009
Japanese biopharma Daiichi Sankyo, which co-owns a long-acting neuraminidase inhibitor for influenza with Australia’s Biota, has applied to manufacture and market the drug in Japan.
The contract depends on the successful completion of Phase III trials in Asia and on obtaining regulatory approval.
The trials have completed patient enrolment with results expected mid-year, Biota said in a statement.
The drug, CS-8958, is a long-acting flu drug which needs less frequent dosing than current neuraminidase inhibitors such as Roche’s oseltamivir (Tamiflu) and Biota’s own zanamivir (Relenza), which is marketed by GSK.
Daiichi Sankyo has rights to the drug in Japan, but Biota said all other key markets are available for licensing by the partners.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
